Literature DB >> 3860298

Phase II trial of 4-demethoxydaunorubicin in patients with advanced malignant melanoma.

G Stanton, E S Casper, B Friedman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3860298

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  5 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 2.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.

Authors:  H C Gillies; D Herriott; R Liang; K Ohashi; H J Rogers; P G Harper
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

Review 4.  Oral idarubicin--an anthracycline derivative with unique properties.

Authors:  M Goebel
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

Review 5.  Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.

Authors:  F Ganzina; M A Pacciarini; N Di Pietro
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.